135,873 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Trexquant Investment LP

Trexquant Investment LP bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 135,873 shares of the biopharmaceutical company’s stock, valued at approximately $6,496,000.

Other hedge funds also recently bought and sold shares of the company. Quantbot Technologies LP acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $150,000. HighTower Advisors LLC boosted its position in shares of Halozyme Therapeutics by 20.2% during the third quarter. HighTower Advisors LLC now owns 36,174 shares of the biopharmaceutical company’s stock worth $2,080,000 after buying an additional 6,075 shares during the period. Janus Henderson Group PLC grew its stake in shares of Halozyme Therapeutics by 6.2% in the third quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company’s stock valued at $31,204,000 after buying an additional 31,871 shares in the last quarter. Stifel Financial Corp raised its holdings in shares of Halozyme Therapeutics by 126.3% in the 3rd quarter. Stifel Financial Corp now owns 17,121 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 9,555 shares during the period. Finally, EP Wealth Advisors LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter worth about $357,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Down 3.5 %

NASDAQ:HALO opened at $59.77 on Friday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. Halozyme Therapeutics, Inc. has a 1 year low of $37.73 and a 1 year high of $66.00. The stock has a market cap of $7.38 billion, a P/E ratio of 17.43, a P/E/G ratio of 0.42 and a beta of 1.32. The stock has a 50-day simple moving average of $59.82 and a 200-day simple moving average of $54.93.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on HALO. HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company cut their target price on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Piper Sandler raised their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research report on Friday, January 10th. Finally, Benchmark reaffirmed a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $62.78.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the completion of the sale, the senior vice president now owns 185,453 shares of the company’s stock, valued at approximately $10,765,546.65. This represents a 5.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,200 shares of company stock worth $1,786,668 in the last ninety days. 2.90% of the stock is owned by corporate insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.